Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet

NCT02589457 on ClinicalTrials.gov Phase 1 Chong Kun Dang Pharmaceutical (industry) Started 2015-10-31 Completed

Among the lowest-risk 1% of active trials

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2015-12-31, after 2015-10-31 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: diseasesitusurgerytreatedsubjects with
Phrases that lowered it: healthyvolunteerstabletmalecompare
Design: crossover (lowers risk) · Design
Accepts healthy volunteers: No (raises risk) · Who can join
Sponsor's past termination rate: 1.6% (lowers risk) · Sponsor's track record
Phase: 1 (lowers risk) · Design
Minimum age: 19 (lowers risk) · Who can join
Disease area, cancer: No (lowers risk) · Disease area
Trials the sponsor started in the prior 2 years: 39 (lowers risk) · Sponsor's track record
Has a data monitoring committee: No (lowers risk) · Design
Drug's FAERS reports with a death: 18.5% (lowers risk) · Drug's FDA history
Sponsor type: industry (lowers risk) · Sponsor's track record
Drug's FAERS reports marked serious: 95.0% (raises risk) · Drug's FDA history
Blinding: none (lowers risk) · Design
Primary purpose: treatment (raises risk) · Design
Maximum age: 45 (lowers risk) · Who can join
Disease area, neurology: No (lowers risk) · Disease area
Sponsor's past trials: 63 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 1 (typical: 2)
Number of arms: 2
Allocation: randomized
Design: crossover (typical: parallel)
Primary purpose: treatment
Blinding: none
Has a data monitoring committee: No (typical: 56% yes)
Responsible party: sponsor
Collaborators: 0
Keywords listed: 3 (typical: 1)

Who can join

Minimum age: 19 (typical: 18)
Maximum age: 45 (typical: 71)
Sex: male (typical: all)
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 63 (typical: 32)
Sponsor's past termination rate: 1.6% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 39 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 2484 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 316 (typical: 412.5)
Drug's FAERS reports marked serious: 95.0% (typical: 85.6%)
Drug's FAERS reports with a death: 18.5% (typical: 15.9%)

Disease area and drugs

Disease areas: infectious disease, digestive
Drugs matched to FDA substances: tenofovir

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers NCT02902523 · started 2016 · scored riskier than 0% of active trials completed
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers NCT02920931 · started 2016 · scored riskier than 0% of active trials completed
Bioequivalence Study of Tenofovir Disoproxil Fumarate Tablets in Healthy Chinese Subjects NCT07558967 · started 2017 · scored riskier than 0% of active trials completed
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants NCT02984852 · started 2016 · scored riskier than 0% of active trials completed
Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination NCT02475135 · started 2015 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.